Quantum BioPharma retains 19.48% Unbuzzd stake

Quantum’s drug candidates address neurodegenerative and metabolic disorders and alcohol misuse disorders at different development stages.

Rhea-AI Filing Summary

Quantum BioPharma Ltd. said the U.S. District Court for the Southern District of New York consolidated its direct action with an investor-led class action and appointed Grant & Eisenhofer P.A. as lead counsel for the class action. Quantum’s action alleges CIBC and RBC and/or their customers used “spoofing” to manipulate its share price between January 1, 2020, and August 15, 2024; the class action alleges harm to shareholders who sold Quantum securities between January 6, 2021, and October 15, 2025. The company said consolidation and counsel appointment are procedural developments, not findings on the merits, liability or damages.

Separately, Quantum retains 19.48% of Unbuzzd as of June 30, 2026. Its agreement with Unbuzzd provides royalties of 7% of sales until payments to Quantum total $250 million, after which the rate becomes 3% in perpetuity. Quantum retains 100% of rights to develop similar products or alternative formulations for pharmaceutical and medical uses. Its wholly owned subsidiary Lucid is researching Lucid-MS, which the company says was shown to prevent and reverse myelin degradation in preclinical models.

Key Figures

Unbuzzd ownership: 19.48% Royalty rate: 7% of sales Cumulative royalty payments threshold: $250 million +2 more

5 metrics

Unbuzzd ownership 19.48% Quantum’s retained ownership as of June 30, 2026

Royalty rate 7% of sales Until payments to Quantum total $250 million

Cumulative royalty payments threshold $250 million Payments to Quantum reach this amount before the royalty rate becomes 3%

Royalty rate thereafter 3% of sales In perpetuity after payments to Quantum total $250 million

Development rights 100% Rights retained to develop similar products or alternative formulations for pharmaceutical and medical uses

Key Terms

preclinical models, new chemical entity, royalty payments, perpetuity

4 terms

preclinical models medical

"in preclinical models"

Laboratory systems—such as cultured cells, tissues, and animal experiments—used to test a drug or medical technology before it is given to people. They act like a prototype or crash-test stage that checks for basic safety, how the treatment works, and whether it’s worth advancing to human trials; investors watch these results because they strongly affect development risk, timelines, and potential costs.

new chemical entity medical

"patented new chemical entity"

A new chemical entity (NCE) is a drug whose active ingredient has never been previously approved or marketed; it’s a wholly new molecule rather than a new use of an existing compound. For investors, NCEs matter because they offer fresh commercial opportunities, potential patent and regulatory exclusivity, and correspondingly higher upside if successful — but they also carry greater development and regulatory risk, like betting on an untested recipe.

royalty payments financial

"royalty payments of 7% of sales"

Payments made to the owner of an asset, patent, trademark, mineral right, or creative work in exchange for permission to use it; they are typically a percentage of sales or a fixed fee per unit sold. For investors, royalty payments represent a steady income stream tied to the underlying product’s sales performance, similar to collecting rent from tenants — predictable cash flow that can reduce risk or add value when evaluating a company’s revenue sources.

perpetuity financial

"3% in perpetuity"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the court decide in QNTM’s consolidated lawsuit?

The U.S. District Court for the Southern District of New York consolidated Quantum’s direct action with an investor-led class action and appointed Grant & Eisenhofer P.A. as lead counsel in the class action. Quantum said these were procedural developments, not a decision on the merits or findings of liability or damages.

What royalty rate does QNTM receive on unbuzzd sales?

Quantum’s agreement with Unbuzzd provides royalties of 7% of sales until payments to Quantum total $250 million, after which the rate becomes 3% in perpetuity.

What is QNTM’s lead compound Lucid-MS?

Lucid-MS is a patented new chemical entity that Quantum says was shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/08/2026 - 08:00 AM Accepted by SEC EDGAR 10/08/2026 - 08:00 AM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Commission File Number: 001-39152

Quantum BioPharma Ltd.
(Translation of registrant's name into English)

1 Adelaide Street East, Suite 801
Toronto, Ontario M5C 2V9
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Quantum BioPharma Ltd.
		(Registrant)
Date: October 8, 2026		/s/ Donal Carroll
		Donal Carroll
		Chief Financial Officer

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press Release dated October 8, 2026

EXHIBIT 99.1

World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that the United States District Court for the Southern District of New York has agreed to consolidate both the Company’s direct action and a class action led by an individual investor alleging market manipulation. In addition, the court appointed experienced law firm Grant & Eisenhofer P.A. (“Grant & Eisenhofer”) as lead counsel in the class action. According to Grant & Eisenhofer, the firm has recovered over USD $30 Billion dollars for its clients to date in some of the most complex, often precedent-setting cases, in fights against the world’s largest and richest opponents.

The Quantum Biopharma lawsuit alleged that between January 1, 2020, and August 15, 2024, the Defendants and/or their customers used “spoofing” techniques to manipulate the share price of Quantum BioPharma shares. The class action lawsuit filed December 11, 2025, alleges that between January 6, 2021, and October 15, 2025, shareholders who sold securities of Quantum Biopharma Ltd., formerly known as FSD Pharma Inc., were significantly and materially harmed.

A link to the Court’s ruling can be found here: Opinion and Order 25-cv-10565 (ER)

For more information visit: www.quantumbiopharma.com under the page Quantum vs Banks.

About Quantum BioPharma Ltd.

Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc. ("Unbuzzd") (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

For more information visit www.quantumbiopharma.com.

Forward-Looking Information

This news release contains “forward-looking statements” within the meaning of applicable securities laws, including the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than statements of historical fact and may include statements regarding the Company’s litigation against the defendants, the effect of the Court’s decision to consolidate the related actions, the conduct and timing of the consolidated litigation, the Company’s ability to pursue its claims, the potential recovery of damages or other relief, and the Company’s expectations regarding the ultimate outcome of the litigation. Forward-looking statements are often identified by words such as “may,” “will,” “should,” “expect,” “anticipate,” “believe,” “intend,” “estimate,” “potential,” “continue,” “could” and similar expressions, although not all forward-looking statements contain these identifying words.

Forward-looking statements are based on management’s current expectations, assumptions and beliefs and are subject to significant risks, uncertainties and other factors that could cause actual results or events to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the inherent uncertainty, cost and duration of litigation; the possibility of appeals, procedural rulings, delays, settlement discussions or other developments; the Company’s ability to prove its allegations and establish liability, causation and damages; the defendants’ defenses and counterarguments; the amount, if any, of damages or other relief that may ultimately be awarded or recovered; the collectability of any judgment or settlement; and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. The Court’s consolidation of the related actions and appointment of lead counsel are procedural developments and do not constitute a determination on the merits of the Company’s claims or any finding of liability or damages. There can be no assurance that the litigation will result in a favorable judgment, settlement, recovery of the amount claimed, or any recovery at all.

Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date hereof and are expressly qualified in their entirety by this cautionary statement. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise.

Contacts:

Investor Relations
Robert Guzman, Investor Relations
Email: Rob@QuantumBioPharma.com
Telephone: (833) 304-0323
General Inquiries: info@QuantumBioPharma.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 7.0 KB